Form 4: Cytokinetics EVP, Chief Commercial Officer Andrew Callos Reports Stock Option Exercise and Sale
SEC Filing
Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics, exercised stock options and sold shares on March 17, 2025.
Summary
- On March 17, 2025, Andrew Callos, the EVP, Chief Commercial Officer of Cytokinetics Inc., exercised non-qualified stock options to acquire 20,900 shares of common stock at a price of $23.26 per share.
- Simultaneously, Callos sold 20,900 shares of common stock at a price of $45.14 per share.
- Following these transactions, Callos directly owns 37,663 shares of Cytokinetics Inc.
- Callos also holds options to purchase 129,000 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency into the trading activities of company executives. It is common for executives to exercise stock options and sell a portion of the acquired shares for personal financial management.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects insider trading activity, which is a normal part of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 03/31/2022 | Date of grant for stock options, which vest over 4 years. |
| 03/17/2025 | Date of transaction: exercise of stock options and sale of shares. |
| 03/31/2031 | Expiration date of the non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.